Serviço de Nutrição, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Av. Brasil 4365, Manguinhos, Rio de Janeiro, Brazil.
Laboratório de Pesquisa Clínica em Doença de Chagas, Instituto de Pesquisa Clínica Evandro Chagas, Fundação Oswaldo Cruz, Av. Brasil 4365, Manguinhos, Rio de Janeiro, Brazil.
Nutr J. 2017 Jun 9;16(1):36. doi: 10.1186/s12937-017-0259-0.
Several studies have been focusing on the effect of omega-3 polyunsaturated fatty acids on modulation of inflammatory markers in several cardiopathies. Although immunoregulatory dysfunction has been associated to the chronic cardiac involvement in Chagas disease, there is no study examining the effects of omega-3 supplementation in these patients. We investigated the effects of omega-3 PUFAs on markers of inflammation and lipid profile in chronic Chagas cardiomyopathy patients.
The present study was a single-center double-blind clinical trial including patients with chronic Chagas cardiomyopathy. Patients were randomly assigned to receive omega-3 PUFAs capsules (1.8g EPA and 1.2g DHA) or placebo (corn oil) during an 8-week period. Cytokines, fasting glucose, lipid, and anthropometric profiles were evaluated.
Forty-two patients (23 women and 19 men) were included in the study and there were only two losses to follow-up during the 8-week period. Most of sociodemographic and clinical characteristics were similar between the groups at baseline, except for the cytokines IL-1β, IL-6, IL-8, IL-10, IL-17α, and IFNγ. The omega-3 PUFAs group demonstrated greater improvements in serum triglycerides (-21.1 vs. -4.1; p = 0.05) and IL-10 levels (-10.6 vs. -35.7; p = 0.01) in comparison to controls after 8 weeks of intervention. No further differences were observed between groups.
Omega-3 PUFAs supplementation may favorably affect lipid and inflammatory profile in chronic Chagas cardiomyopathy patients, demonstrated by a decrease in triglycerides and improvements on IL-10 concentration. Further studies examining the clinical effects of omega-3 fatty acids supplementation in chronic Chagas cardiomyopathy are necessary.
NCT01863576.
多项研究已聚焦于ω-3 多不饱和脂肪酸对多种心脏疾病中炎症标志物的调节作用。虽然免疫调节功能障碍与恰加斯病的慢性心脏受累相关，但目前尚无研究检查ω-3 补充剂对这些患者的影响。我们研究了 ω-3 多不饱和脂肪酸对慢性恰加斯心肌病患者炎症和血脂谱标志物的影响。
本研究为一项单中心、双盲临床试验，纳入了慢性恰加斯心肌病患者。患者随机分配在 8 周期间接受 ω-3 多不饱和脂肪酸胶囊（1.8g EPA 和 1.2g DHA）或安慰剂（玉米油）治疗。评估细胞因子、空腹血糖、血脂和人体测量参数。
42 例患者（23 名女性和 19 名男性）纳入了研究，在 8 周期间仅发生了 2 例失访。除细胞因子 IL-1β、IL-6、IL-8、IL-10、IL-17α 和 IFNγ 外，两组患者的大多数社会人口学和临床特征在基线时相似。与对照组相比，ω-3 多不饱和脂肪酸组在 8 周干预后血清甘油三酯（-21.1 对-4.1；p=0.05）和 IL-10 水平（-10.6 对-35.7；p=0.01）的改善更为显著。两组之间未观察到进一步的差异。
ω-3 多不饱和脂肪酸补充可能对慢性恰加斯心肌病患者的脂质和炎症谱产生有利影响，表现为甘油三酯降低和 IL-10 浓度改善。需要进一步研究检查 ω-3 脂肪酸补充对慢性恰加斯心肌病的临床效果。
NCT01863576。
